Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The Informa Pharma Intelligence webinar recording is now available to watch, Biosimilars Development in Autoimmune and Inflammatory Diseases
We hope you find the recording of the webinar helpful in gaining insight into the factors driving the biosimilars market for blockbuster drug trials helpful.
Information for the Biosimilars Development in Autoimmune and Inflammatory Diseases webinar came from resources that are part of the Informa Pharma Intelligence family of tools. Trusted by over 3,000 of the world’s leading pharmaceutical companies, CRO’s, med and biotech organizations, and healthcare service providers, Pharma Intelligence delivers vital, accurate, and timely intelligence about the drug development pipeline. Pharma Intelligence tools feature continually updated data, global teams of subject area experts, and comprehensive support that is unparalleled anywhere else in the industry.
Biosimilars Development in Autoimmune and Inflammatory Diseases webinar recording
Datamonitor Healthcare: data analysis and insight
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
Datamonitor Healthcare: data analysis and insight
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topics Cancer
Datamonitor Healthcare: data analysis and insight
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
